(Date:12/14/2009)... - Results From a Survey Conducted ... Seven Major Industrialized Countries , , - ... disease, impacts their enjoyment of ... rheumatoid arthritis find shopping for gifts, ... difficult to do, ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused ... therapeutics for cardiovascular and muscle disease, today announced ... plays a crucial role in the progression of ... and in neuromuscular synaptic regeneration in mice. ... of the journal Science , reveal miR-206 ...
(Date:12/11/2009)... Ambit Biosciences Corporation announced today the enrollment ... Anderson Cancer Center of the first patient in the ... E fficacy) Phase 2 pivotal trial in patients ... AC220 is a novel, orally available, potent and highly ... FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study ...
(Date:12/11/2009)... Gwathmey, Inc., a pre-clinical contract research organization and ... cardiovascular disease announces a new CEO. ... Ph.D., has joined Gwathmey as Chief Executive Officer. ... experience working with small businesses and the federal ... managed multimillion dollar portfolios for the National Institutes ...
Breaking Biology Technology:Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 2Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 3Rheumatoid Arthritis Patients Want Pain-Free Days at Christmas 4miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer 2... CAMBRIDGE, Mass., July 2 Biopure Corporation,(Nasdaq: BPUR ... with,purchasers for a private placement of its common stock ... no exercise of the warrants. The,company intends to use ... The first closing occurred on June 30, 2008, and,subsequent ...
... Vice President, Marketing and Sales; Susan Koppy ... as Vice President, Corporate Development, PT. RICHMOND, Calif., July ... Moore to the position of,Vice President, Marketing and Sales and ... Mr. Moore and Ms. Koppy will report,to President & Chief ...
... 2 Pearl Therapeutics, Inc.,a biopharmaceutical company developing ... has completed the closing of an $18,million round ... extension to,its first venture financing, which closed in ... existing investors Clarus Ventures, New Leaf,Ventures, 5AM Ventures ...
Other Biology Technology:Biopure Announces Private Equity Financing 2Biopure Announces Private Equity Financing 3Transcept Pharmaceuticals Appoints Key Senior Executives 2Transcept Pharmaceuticals Appoints Key Senior Executives 3Transcept Pharmaceuticals Appoints Key Senior Executives 4Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors 2... quality running into billions of dollars ... increasing pressure to reduce expensive rework ... distribution of ingredients is known to ... dissolution, stability, bio-availability and hardness. However, ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. ID clarifier: rack ...
... , ,Product Information , ,The three ... is extremely efficient, yet gentle, making this ... as staining gels, hybridization and other applications. ... broad range. A nonslip rubber mat and ...
Biology Products:Biology NavigationMedical Navigation